Suppr超能文献

口服疟疾疗法:负载姜黄素的脂质基药物传递系统结合β-青蒿素醚。

An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with β-arteether.

机构信息

Université catholique de Louvain, Louvain Drug Research Institute, Pharmaceutics and drug delivery group, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium; University of Kinshasa, Faculty of Pharmaceutical Sciences, Laboratoire de Pharmacie galénique, BP 212 Kinshasa XI, Democratic Republic of Congo.

出版信息

J Control Release. 2013 Dec 28;172(3):904-13. doi: 10.1016/j.jconrel.2013.09.001. Epub 2013 Sep 7.

Abstract

Curcumin (CC), a potential antimalarial drug, has poor water solubility, stability and oral bioavailability. To circumvent these pitfalls, lipid-based drug delivery systems (LBDDSs) with a high CC loading (30 mg/g) were formulated. In a biorelevant gastric medium, CC-LBDDSs formed particle sizes in the range of 30-40 nm. During in vitro lipolysis, 90-95% of the CC remained solubilized, whereas 5-10% of the CC precipitated as an amorphous solid, with a high rate of re-dissolution in a biorelevant intestinal medium. The transport of the CC-LBDDS across Caco-2 monolayers was enhanced compared with the transport of free drug because of the increased CC solubility. In Plasmodium berghei-infected mice, modest antimalarial efficacy was observed following oral treatment with CC-LBDDSs. However, the combination therapy of CC-LBDDS with a subtherapeutic dose of β-arteether-LBDDS provided an increase in protection and survival rate that was associated with a significant delay in recrudescence. These findings suggest that the combination of oral CC and β-arteether lipid-based formulations may constitute a promising approach for the treatment of malaria.

摘要

姜黄素(CC)是一种有潜力的抗疟药物,但水溶性、稳定性和口服生物利用度较差。为了克服这些问题,我们制备了载药量高(30mg/g)的基于脂质的药物传递系统(LBDDS)。在生物相关的胃介质中,CC-LBDDS 的粒径在 30-40nm 范围内。在体外脂肪酶解过程中,90-95%的 CC 保持溶解,而 5-10%的 CC 沉淀为无定形固体,在生物相关的肠介质中有很高的再溶解速率。与游离药物相比,CC-LBDDS 跨 Caco-2 单层的转运能力增强,因为 CC 的溶解度增加。在感染伯氏疟原虫的小鼠中,经口给予 CC-LBDDS 后观察到适度的抗疟疗效。然而,CC-LBDDS 与亚治疗剂量的β-青蒿素-LBDDS 联合治疗提供了更高的保护率和生存率,与复燃的显著延迟相关。这些发现表明,口服 CC 和β-青蒿素脂质制剂的联合应用可能成为治疗疟疾的一种有前途的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验